In this updated pooled safety analysis from clinical trials of PsO, PsA & axSpA pts given SEC 150 &/or 300mg SC (ADeodhar et al) ⬆️freq AEs: nasopharyngitis & URTI Low EAIRs/100pt yrs for IBD, malignancies & MACE No new safety signals Reassuring data. #ACR23 ABST1436 @RheumNow https://t.co/guF0gC4hQM